Nilogen Oncosystems is dedicated to streamlining and improving drug development in cancer and immuno-oncology. At Nilogen, we appreciate the complexity of cancer and use fresh patient tumor samples with intact tumor immune microenvironment in our preclinical drug testing platforms. This allows us to see the whole picture for a better understanding of the molecular mechanisms of drug sensitivity and resistance. These proprietary and innovative platforms aim to significantly reduce the cost and risk associated with clinical trials. Nilogen’s commitment to testing and customizing cancer drug development is proven and yields unparalleled results for its clients.
